Israel’s RedHill Biopharma announced success last week in a major clinical trial of a new drug to prevent nausea in cancer patients.
The once-a-day pill RHB-102, which has now passed a trial corresponding to a Phase III clinical trial, will compete with leading anti-nausea drug Zofran, made by GlaxoSmithKline, which is taken several times a day.
Redhill will apply to the FDA for a pre-New Drug Application hearing for market approval in a few weeks.
Anti-nausea medications are estimated to be worth $2 billion around the world, according to a report in Globes online business news.
About the Author: Malkah Fleisher is a graduate of Cardozo Law School in New York City. She is an editor/staff writer at JewishPress.com and co-hosts a weekly Israeli FM radio show. Malkah lives with her husband and two children on the Mount of Olives in Jerusalem.
If you don't see your comment after publishing it, refresh the page.